Advertisement

Topics

Response after single treatment with canakinumab predicts which patients will benefit most

10:02 EST 13 Nov 2017 | Science Daily

A pre-specified analysis on CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcomes Study) that identifies a simple, clinical method to define patient groups most likely to benefit from long-term canakinumab treatment.

Original Article: Response after single treatment with canakinumab predicts which patients will benefit most

NEXT ARTICLE

More From BioPortfolio on "Response after single treatment with canakinumab predicts which patients will benefit most"

Advertisement
Quick Search
Advertisement
Advertisement